Home » Stocks » Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. (KALA)

Stock Price: $10.56 USD -0.09 (-0.85%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 588.36M
Revenue (ttm) 5.76M
Net Income (ttm) -90.91M
Shares Out 55.72M
EPS (ttm) -2.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $10.56
Previous Close $10.65
Change ($) -0.09
Change (%) -0.85%
Day's Open 10.91
Day's Range 10.31 - 10.98
Day's Volume 589,339
52-Week Range 3.24 - 14.68

More Stats

Market Cap 588.36M
Enterprise Value 480.44M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 55.72M
Float 33.19M
EPS (basic) -2.55
EPS (diluted) -2.53
FCF / Share -2.03
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.60M
Short Ratio 3.71
Short % of Float 9.17%
Beta 0.35
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 102.16
PB Ratio 5.24
Revenue 5.76M
Operating Income -84.30M
Net Income -90.91M
Free Cash Flow -82.61M
Net Cash 107.92M
Net Cash / Share 1.94
Gross Margin 70.60%
Operating Margin -1,463.78%
Profit Margin -1,578.60%
FCF Margin -1,434.50%
ROA -23.13%
ROE -81.22%
ROIC -69.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(109.94% upside)
Current: 10.56
Target: 22.17
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit4.07---0.05
Operating Income-88.22-64.72-39.88-32.67-15.95
Net Income-94.35-66.74-42.21-33.17-16.68
Shares Outstanding34.2126.7511.381.181.12
Earnings Per Share-2.76-2.49-3.71-28.07-14.89
Operating Cash Flow-92.72-54.12-34.10-27.35-15.09
Capital Expenditures-1.34-1.58-0.48-0.15-0.25
Free Cash Flow-94.06-55.70-34.58-27.50-15.34
Cash & Equivalents98.0318311545.585.87
Total Debt10199.4418.659.659.80
Net Cash / Debt-3.1583.6696.0535.93-3.93
Book Value29.6910589.68-87.76-56.66
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kala Pharmaceuticals, Inc.
Country United States
Employees 136
CEO Mark T. Iwicki

Stock Information

Ticker Symbol KALA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KALA
IPO Date July 20, 2017


Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.